David A. Rodriguez
On August 4, 2026, David A. Rodriguez retired from the Board of Directors of Globe Life Inc. (the “Company”), effective immediately, for personal reasons.
Highest-materiality recent filing
Globe Life Q2 EPS $3.65 beats $3.05 YoY; raises FY guidance to $15.55-$15.95
Net income per diluted share $3.65 vs $3.05 YoY (+20%); net operating income per share $3.61 vs $3.27 (+10%).
Globe Life Q1 EPS $3.39 vs $3.01 YoY; raises FY2026 guidance to $15.40-$15.90
Net operating income per share $3.43, up 12% YoY; net income per share $3.39, up 13% YoY.
Q4 net income $3.29/share vs $3.01 YoY; net operating income $3.39 vs $3.14, up 8%.
Globe Life Q3 net income $4.73/share, up 38% YoY; FY2025 guidance $14.40-$14.60
Net income per diluted share $4.73 vs $3.44 YoY; net operating income $4.81 vs $3.49 YoY.
Globe Life announces SEC investigation concluded with no enforcement action; DOJ also closes probe
SEC staff notified Globe Life they have concluded investigation and do not intend to recommend enforcement action.
Globe Life Q2 net income $3.05/sh (up 8% YoY); operating EPS $3.27 (up 10%)
Net income per diluted share $3.05 (+8% YoY); operating EPS $3.27 (+10%).
Globe Life closes $500M P-Caps issuance for contingent liquidity facility due 2055
Issued 500,000 P-Caps at $1,000 each for $500M total; trust invested proceeds in U.S. Treasury strips.
Globe Life Q1 net op income $3.07/sh, beats expectations; net income $3.01/sh, +13% YoY
Net operating income $3.07 per diluted share vs $2.78 YoY (+10%), above management expectations.
Globe Life Q4 net operating income $3.14 vs $2.80 YoY; guides FY2025 $13.45-$14.05
Q4 net operating income $3.14/diluted share (up 12% YoY); net income $3.01/diluted share.
Threat actor obtained PII of ~5,000 individuals (names, SSNs, health data, etc.); no financial data.
Globe Life Q3 NOI $3.49, up 29% YoY; guides FY24 $12.20-12.40, FY25 $13.20-13.90
Q3 net income $3.44/diluted share vs. $2.68 YoY; net operating income $3.49 vs. $2.71 YoY (19% increase).
Net income $258.4M ($2.83 diluted) vs $215.3M ($2.24) in Q2 2023; net operating income $271.2M ($2.97) vs $251.5M ($2.61).
Globe Life audit committee finds no merit to short-seller allegations after independent review
Audit Committee completed independent investigation of allegations by Fuzzy Panda Research and Viceroy Research.
On June 13, 2024, following a state regulator inquiry, Globe Life found likely unauthorized access to consumer/policyholder info via a web portal's access permissions.
Globe Life Q1 net income $2.67/sh, up 14% YoY; guides FY NOI $11.50-$12.00
Net income $254.2M ($2.67/diluted share) vs $223.6M ($2.28) YoY; net operating income $264.1M ($2.78) vs $248.0M ($2.53).
Globe Life upsizes revolving credit facility to $1.0B, extends maturity to 2029
Revolving credit facility increased from $750M to $1.0B; ability to request further increase up to $1.25B.
Former agent's claims against AIL and Arias dismissed with prejudice; no payment or relief obtained.
Globe Life Q4 net income $2.88/share, up 17%; FY2024 operating EPS guide $11.30-$11.80
Net income $274.8M ($2.88/diluted share) vs $242.3M ($2.46) YoY; net operating income $267.4M ($2.80) vs $251.3M ($2.55).
Globe Life Q3 net income $2.68/diluted, up 38% YoY; net operating income $2.71
Net income per diluted share $2.68 vs $1.94 YoY; net operating income $2.71 vs $2.19.
Globe Life Q2 operating income $2.61/sh (+3% YoY); guides FY23 $10.37-$10.57/sh
Net income $2.24/sh ($215.3M), down from $2.26/sh; net operating income $2.61/sh ($251.5M), up 3% from $2.54/sh.
Globe Life Q1 net income $2.28/diluted share vs $2.37 YoY; operating income $2.53, up 4%
Net income $2.28/diluted share vs $2.37 YoY; net operating income $2.53 vs $2.43 (+4%).
Globe Life Q4 net income $2.14 per share, up 22% YoY; FY 2023 guidance $10.20-$10.50
Net income per share $2.14 (Q4 2022) vs $1.76 a year ago; net operating income $2.24 vs $1.70.
Globe Life Q3 net operating income $2.15/sh, +21% YoY; issues 2023 guidance
Net operating income per diluted share $2.15 vs $1.78 in Q3 2021, up 21%.
Coleman and Hutchison step down as co-CEOs; Darden and Svoboda to succeed Jan 1, 2023
Co-CEOs Coleman and Hutchison retire as CEOs effective Dec 31, 2022, remain co-chairmen.
Globe Life Q2 operating EPS $2.07, up 12% YoY; guides FY $7.90-$8.30; repurchases 1.4M shares
Net operating EPS $2.07 vs $1.85, +12% YoY; net income EPS $1.79 vs $1.92.
Globe Life Q1 net op income $1.70/share, up 11% YoY; cuts FY2022 guidance on COVID claims
Net operating income $1.70/diluted share, up 11% YoY; net income $1.64/diluted share, down 4% YoY.
On August 4, 2026, David A. Rodriguez retired from the Board of Directors of Globe Life Inc. (the “Company”), effective immediately, for personal reasons.
Linda L. Addison and Marilyn A. Alexander retired from the Globe Life Inc. Board of Directors at the Annual Meeting of Shareholders on April 30, 2026.
Linda L. Addison and Marilyn A. Alexander retired from the Globe Life Inc. Board of Directors at the Annual Meeting of Shareholders on April 30, 2026.
Steven P. Johnson retired from the Globe Life Inc. Board of Directors at the Annual Meeting of Shareholders on April 24, 2025.
appointed Matthew J. Adams and Philip M. Jacobs to fill the newly-created directorships.
appointed Matthew J. Adams and Philip M. Jacobs to fill the newly-created directorships.
Jane Buchan retired from the Globe Life Inc. Board of Directors at the Annual Meeting of Shareholders on April 25, 2024.
The Board appointed Alice S. Cho and David A. Rodriguez to fill the newly-created directorships.
The Board appointed Alice S. Cho and David A. Rodriguez to fill the newly-created directorships.
Darren M. Rebelez notified the Board of his intention to retire as a director of the Company at the Annual Meeting of Shareholders on April 27, 2023, and not stand for re-election.
It is the present intention of the Board for Globe Life’s Co-Chief Executive Officers, J. Matthew Darden and Frank M. Svoboda, to succeed Messrs. Coleman and Hutchison as Co-Chairmen of the Board upon their retirement and contingent upon Messrs. Darden and Svoboda’s election to the Board at the Annual Meeting.
It is the present intention of the Board for Globe Life’s Co-Chief Executive Officers, J. Matthew Darden and Frank M. Svoboda, to succeed Messrs. Coleman and Hutchison as Co-Chairmen of the Board upon their retirement and contingent upon Messrs. Darden and Svoboda’s election to the Board at the Annual Meeting.
Max materiality 0.85 · Median 0.60 · Most common event earnings